Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Monoisotopic mass
439.174335547
InChI
InChI=1S/C23H25N3O6/c1-30-20(27)12-17-11-18(25-22(17)28)13-32-19-9-7-15(8-10-19)14-3-5-16(6-4-14)21(24)26-23(29)31-2/h3-10,17-18H,11-13H2,1-2H3,(H,25,28)(H2,24,26,29)/t17-,18-/m0/s1
InChI Key
InChIKey=PGCFXITVMNNKON-ROUUACIJSA-N
IUPAC Name
methyl 2-[(3S,5S)-5-(4-{4-[(1Z)-amino[(methoxycarbonyl)imino]methyl]phenyl}phenoxymethyl)-2-oxopyrrolidin-3-yl]acetate
Traditional IUPAC Name
methyl 2-[(3S,5S)-5-(4-{4-[(1Z)-amino[(methoxycarbonyl)imino]methyl]phenyl}phenoxymethyl)-2-oxopyrrolidin-3-yl]acetate
SMILES
COC(=O)C[C@@H]1C[C@@H](COC2=CC=C(C=C2)C2=CC=C(C=C2)C(\N)=N\C(=O)OC)NC1=O
pKa (strongest acidic)
14
pKa (Strongest Basic)
0.71
Refractivity
115.47 m3·mol-1
Dược Lực Học :
Lefradafiban, an orally active prodrug of fradafiban, is a novel glycoprotein (IIb/IIIa) inhibitor for the treatment of unstable angina. Development was discontinued in 2000 due to lack of efficacy.
Cơ Chế Tác Dụng :
Lefradafiban is an oral platelet glycoprotein IIb/IIIa receptor antagonist being investigated in the treatment of angina.
GPIIb/IIIa inhibitors, such as lefradafiban, block the final common pathway of platelet aggregation.
Chỉ Định :
For the treatment of unstable angina.